Selectivity, binding affinity, and ionization state of matrix metalloproteinase inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 26, 2013, Pages 4701-4713

  Zhong, Haizhen A ^a   Arbiser, Jack ^b,c   Bowen, J Phillip ^d  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d MERCER UNIVERSITY   (United States)

Author keywords

And zinc binding group; Cancer; Docking; MMP 13; MMP 2; MMP 3; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; ABT 518; COLLAGENASE 3; GELATINASE A; GELATINASE B; HYDROXAMIC ACID; ILOMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; RS 113456; SC 77774; SM 25453; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; VORINOSTAT; ZINC BINDING PROTEIN; ZINC ION;

ARTICLE; BINDING AFFINITY; CANCER GROWTH; CANCER PROGNOSIS; CRYSTAL STRUCTURE; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; IC 50; IONIZATION; MOLECULAR DOCKING; NONHUMAN; OSTEOARTHRITIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTON TRANSPORT; RHEUMATOID ARTHRITIS; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; MATRIX METALLOPROTEINASES; MOLECULAR SEQUENCE DATA; PROTEASE INHIBITORS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84881350248     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319260004     Document Type: Article

References (82)

1. Weinstat-Saslow DL, Zabrenetzky VS, vanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994; 54: 6504-11.
2. Whittaker M, Floyd CD, Bowen P, Gearing AJH. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999; 99: 2735-76.
3. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenviroment. Cell 2010; 141: 52-67.
4. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007; 104: 20262-7.
5. Yadav RK, Gupta SP, Sharma PK, Patil VM. Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review. Curr Med Chem 2011; 18:1704-22.
6. Gupta SP. Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors. Chem Rev 2007; 107: 3042-87.
7. Tu G, Xu W, Huang H, Li S. Progress in the development of matrix metalloproteinase inhibitors. Curr Med Chem 2008; 15: 1388-95.
8. Bissett D, O'Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005; 23: 842-9.
9. Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003; 48: 1742-9.
10. Hutchinson JW, Tierney GM, Parsons SL, Davis TR. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 1998; 80(5): 907-8.
11. Yu W, Tong L, Kim SH, et al. Biaryl substituted hydantoin compounds as TACE inhibitors. Bioorg Med Chem Lett. 2010; 20(17): 5286-9.
12. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434-9.
13. Rao BG. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 2005; 11(3): 295-322.
14. Wada CK. The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories. Curr Top Med Chem 2004; 4(12): 1255-67.
15. Hirte H, Vergote IB, Jeffrey JR, et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 2006; 102(2): 300-8.
16. Nozaki S, Sissons S, Chien DS, Sledge GW Jr. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model. Clin Exp Metastasis 2003; 20(5): 407-12.
17. Wu J, Rush TS III, Hotchandani R, et al. Identification of potent and selective MMP-13 inhibitors. Bioorg Med Chem Lett 2005; 15(18): 4105-9.
18. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000; 97(8): 4052-7.
19. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011; 23(5): 471-8.
20. Zreiqat H, Belluoccio D, Smith MM, et al. S100A8 and S100A9 in experimental osteoarthritis. Arthritis Res Ther 2010; 12(1): R16.
21. Welch AR, Holman CM, Huber M, Brenner MC, Browner MF, Van Wart HE. Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. Biochemistry 1996; 35(31): 10103-9.
22. Browner MF, Smith WW, Castelhano AL. Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry 1995; 34(20): 6602-10.
23. Lovejoy B, Welch AR, Carr S, et al. Crystal structures of MMP-1 and-13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 1999; 6(3): 217-21.
24. Huang A, Joseph-McCarthy D, Lovering F, et al. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. Bioorg Med Chem 2007; 15(18): 6170-81.
25. Kohno T, Hochigai H, Yamashita E, Tsukihara T, Kanaoka M. Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453. Biochem Biophys Res Commun 2006; 344(1): 315-22.
26. Kolodziej SA, Hockerman SL, Boehm TL, et al. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alphasulfone hydroxamates. Bioorg Med Chem Lett 2010; 20(12): 3557-60.
27. Becker DP, Barta TE, Bedell LJ, et al. Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. J Med Chem 2010; 53(18): 6653-80.
28. Nuti E, Casalini F, Avramova SI, et al. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. J Med Chem 2009; 52(15): 4757-73.
29. Becker DP, Barta TE, Bedell L, et al. Alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1. Bioorg Med Chem Lett 2001; 11(20): 2719-22.
30. Li JJ, Nahra J, Johnson AR, et al. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. J Med Chem 2008; 51(4): 835-41.
31. Li W, Hu Y, Li J, et al. 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding. Bioorg Med Chem Lett 2009; 19(16): 4546-50.
32. Monovich LG, Tommasi RA, Fujimoto RA, et al. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13. J Med Chem 2009; 52(11): 3523-38.
33. Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007; 282(38): 27781-91.
34. Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009; 60(7): 2008-18.
35. Gao DA, Xiong Z, Heim-Riether A, et al. SAR studies of non-zincchelating MMP-13 inhibitors: improving selectivity and metabolic stability. Bioorg Med Chem Lett 2010; 20(17): 5039-43.
36. Heim-Riether A, Taylor SJ, Liang S, et al. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors. Bioorg Med Chem Lett 2009; 19(18): 5321-4.
37. Roth J, Minond D, Darout E, et al. Identification of novel, exositebinding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med Chem Lett 2011; 21(23): 7180-4.
38. Blagg JA, Noe MC, Wolf-Gouveia LA, et al. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett 2005; 15(7): 1807-10.
39. Cege C, Bao B, Bluhm H, et al. Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. J Med Chem 2012; 55 (2): 709-16.
40. Taylor SJ, Abeywardane A, Liang S, et al. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem 2011; 54(23): 8174-87.
41. Marques SM, Tuccinardi T, Nuti E, et al. Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases J Med Chem 2011; 54 (24): 8289-98.
42. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278(1): 16-27.
43. Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV 3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via V3 integrin. Cancer Cell 2003; 3: 589-601.
44. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
45. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007; 104: 20262-67.
46. Festuccia C, Bologna M, Vicentini C, et al. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer 1996; 69(5): 386-93.
47. Castellano G, Malaponte G, Mazzarino MC, et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 2008; 14(22): 7470-80.
48. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node positive breast carcinoma. Clin Cancer Res 2004; 10: 1057-63.
49. Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and-9 to predict breast cancer progression. Clin Biochem 2011; 44(10-11): 869-72.
50. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase Adeficient mice. Cancer Res 1998; 58(5): 1048-51.
51. Cheng M, De B, Pikul S, et al. Design and synthesis of piperazinebased matrix metalloproteinase inhibitors. J Med Chem 2000; 43(3): 369-80.
52. Hajduk PJ, Sheppard G, Nettesheim DG, et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc 1997; 119(25): 5818-27.
53. Wada CK, Holms JH, Curtin ML, et al. Phenoxyphenyl sulfone Nformylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J Med Chem 2002; 45(1): 219-32.
54. Qu X, Yuan Y, Xu W, et al. Caffeoyl pyrrolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity. Anticancer Res 2006; 26(5A): 3573-8.
55. Cheng XC, Wang Q, Fang H, Tang W, Xu WF. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. Bioorg Med Chem 2008; 16(10): 5398-404.
56. Wang J, S'Sullivan S, Harmon S, et al. Design of barbituratenitrate hybrids that inhibit MMP-9 activity and secretion. J Med Chem 2012; Just Accepted Manuscript, DOI: 10.1021/jm201352k
57. Wang J, Medina C, Radomski MW, Gilmer JF. N-substituted homopiperazine barbiturates as gelatinase inhibitors. Bioorg Med Chem 2011; 19(16): 4985-99.
58. Ledour G, Moroy G, Rouffet M, et al. Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. Bioorg Med Chem 2008; 16(18): 8745-59.
59. Rubino MT, Agamennone M, Campestre C, et al. Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors. ChemMedChem 2009; 4(3): 352-62.
60. Ikejiri M, Bernardo MM, Meroueh SO, et al. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 2005; 70(14): 5709-12.
61. Testero SA, Lee M, Staran RT, et al. Sulfonate-containing thiiranes as selective gelatinase inhibitors. ACS Med Chem Lett 2011; 2: 177-81.
62. Testero SA, Llarrull LI, Fisher JF, Chang M, Mobashery S. Exploring the functional space of thiiranes as gelatinase inhibitors using click chemistry. ARKIVOC 2011; 7: 221-36.
63. Brown S, Bernardo M, Li ZH, et al. Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 2000; 122: 6799-800.
64. Zhang Y, Fang H, Feng J, Jia Y, Wang X, Xu W. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. J Med Chem 2011; 54(15): 5532-9.
65. Marques SM, Nuti E, Rossello A, et al. Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates. J Med Chem 2008; 51(24): 7968-79.
66. Zhu Z, Mazzola R, Sinning L, et al. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes. J Med Chem 2008; 51(4): 725-36.
67. Tochowicz A. Maskos K, Huber R, et al. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol 2007; 371: 989-1006.
68. Zhang W, Hou TJ, Qiao XB, Huai S, Xu XJ. Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2. J Mol Model 2004; 10: 112-20.
69. Gupta SP, Kumaran S. A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors. Bioorg Med Chem 2005; 13: 5454-62.
70. Gupta SP, Kumar D, Kumaran SA. Quantitative structure-activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. Bioorg Med Chem 2003; 11: 1975-81.
71. Tuccinardi T, Nuti E, Ortore G, Rossello A, Avramova SI, Martinelli A. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors. Bioorg Med Chem 2008; 16(16): 7749-58.
72. Tuccinardi T, Ortore G, Santos MA, et al. Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors. J Chem Inf Model 2009; 49(7): 1715-24.
73. Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta 2010; 1803(1): 72-94.
74. Roswell S, Hawtin P, Minshull CA, et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol 2002; 319: 173-81.
75. Glide, Schrödinger, LLC. Portland, OR. U.S.A. Web address: www.schrodinger.com, 2009.
76. Zhong H, Wees MA, Faure TD, Carrillo C, Arbiser J, Bowen JP. The impact of ionization states of matrix metalloproteinase inhibitors on docking-based inhibitor design. ACS Med Chem Lett 2011; 2: 455-460.
77. Jain T, Jayaram B. Computational protocol for predicting the binding affinities of zinc containing metalloprotein-ligand complexes. Proteins: Struct Funct Bioinfo 2007; 67: 1167-78.
78. Díaz N, Suárez D. Peptide hydrolysis catalyzed by matrix metalloprotein 2: A computational study. J Phys Chem B 2008; 112: 8412-24.
79. Zhou J, Tao P, Fisher JF, Shi Q, Mobashery S, Schlegel HB. QM/MM studies of the matrix metalloproteinase 2 (MMP2) inhibition mechanism of (S)-SB-3CT and its oxirane analogue. J Chem Theory Comput 2010; 6: 3580-7.
80. Dejonckheere E, Vandenbroucke RE, Libert C. Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. Cytokine Growth Factor Rev 2011; 22(2): 73-81.
81. Garbacki N, Di Valentin E, Piette J, Cataldo D, Crahay C, Colige A. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Pulm Pharmacol Ther 2009; 22(4): 267-78.
82. Decock J, Thirkettle S, Wagstaff L, Edwards DR. Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med 2011; 15(6): 1254-65.